MedTrace Logo

Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

NCT04874129 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-05-05

No results posted yet for this study

Summary

To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A

Conditions

  • Dyslipidemias

Interventions

DRUG

YYC506-T and YYC506-A (phase 1)

Comparator

DRUG

YYC506 (phase 1)

Test

DRUG

YYC506-T and YYC506-A (phase 2)

Comparator

DRUG

YYC506 (phase 2)

Test

Sponsors & Collaborators

  • Yooyoung Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Min Kyu Park, PhD · Chungbuk National University Hosipital.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-07
Primary Completion
2021-05-31
Completion
2021-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04874129 on ClinicalTrials.gov